This is the authors' abstract. We don't add key points for this paper.
Omalizumab may provide a new treatment strategy for allergic rhinitis. The high cost of omalizumab precludes its chronic use for allergic rhinitis and it is not FDA approved for this indication; however, its periodic use may be justified in treatment resistant patients, especially those with seasonal disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Vashisht et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: